ArticleFrontiers in endocrinology2026
Development and external validation of a risk prediction model for hypertension among individuals with established hypothyroidism.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypothyroidism represents a multisystem endocrine disorder involving cardiovascular, renal, and metabolic alterations beyond thyroid hormone deficiency. However, validated tools for hypertension (HTN) risk stratification specifically designed for patients with hypothyroidism remain lacking. This study aimed to develop and externally validate a hypothyroidism-specific HTN prediction model incorporating routinely available clinical variables. Methods: This retrospective multicohort study included patients with hypothyroidism from a hospital-based cohort and an independent external population-based cohort. Eligible participants were identified according to predefined diagnostic criteria, and individuals with missing key clinical variables or incomplete outcome information were excluded. Candidate predictors were selected using regression-based approaches, and a multivariable prediction model was developed in the derivation cohort and subsequently evaluated in internal and external validation cohorts. An interpretable HTN risk profile was developed and evaluated using internal validation, external validation, and subgroup analyses. Results: Age, serum creatinine (SCr), anion gap (AG), and diabetes mellitus (DM) constituted a clinically interpretable risk profile reflecting vascular aging, renal vulnerability, and metabolic dysregulation. The model demonstrated robust discrimination, good calibration, and favorable clinical utility across training, testing, and external validation cohorts. Conclusions: A disease specific HTN risk profile was developed and externally validated in patients with hypothyroidism. This model provides a practical approach for individualized cardiovascular risk stratification and supports the application of precision endocrine medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.